MADISON, Wis., April 18, 2019-- Imbed Biosciences Inc. (Imbed), a medical device company emerging as a leader in the development of advanced therapies for soft tissue repair, announced today that it has closed $2 million in a Series A Preferred Stock equity financing. The funding will be used to commercialize company’s FDA-cleared MicroLyte® Ag Antimicrobial Matrix indicated for the management of chronic ulcers, burns, and surgical wounds.